HTD1801 Shows Promise for Polycystic Kidney Disease
The drug candidate reduces cyst expansion in lab-grown kidney models, signaling a potential path for future clinical study.
Updated on Oct. 23, 2026 in Biotech
Live Poll
Do you trust emerging medical research to provide meaningful improvements for chronic health conditions?
HighTide Therapeutics has announced preclinical results showing that its drug candidate HTD1801 reduces cyst expansion in models of autosomal dominant polycystic kidney disease (ADPKD). This research-stage development demonstrated a significant reduction in cystic area fraction compared to control groups.
Why it matters
The findings address the ongoing need for disease-modifying therapies for ADPKD, a condition where 50% of patients progress to kidney failure by age 60. By targeting cellular pathways associated with cyst growth, the drug aims to slow disease progression.
In nephron organoids, HTD1801 reduced the median cystic area fraction to 10.70% compared to 20.40% in untreated controls. The treatment also increased the proportion of organoids showing low cystic burden to 97.3%.
The players
HighTide Therapeutics
A clinical-stage biotechnology company focused on developing therapies for metabolic and digestive diseases.
The details
The study utilized PKD1-/- human iPSC-derived nephron organoids—lab-grown tissue clusters that mimic kidney structure—subjected to forskolin to induce cyst expansion. HTD1801 functions by activating AMPK, an enzyme that regulates cellular energy, to suppress cAMP-driven epithelial cyst proliferation. Additionally, the drug inhibits NLRP3, a protein complex involved in inflammation, to further curb renal damage.
Timeline
October 22, 2026: Data was presented at the American Society of Nephrology annual meeting.
The Tech Race
This development marks a new data point in the competition to find pharmacologic alternatives to the standard-of-care treatments for ADPKD. HighTide Therapeutics is now positioned among research groups testing AMPK-NLRP3 axis modulation as a viable path for slowing kidney degeneration.
This drug remains in the preclinical stage, meaning it is not currently available for patient use or clinical application. HighTide Therapeutics intends to proceed with further clinical investigation, though no specific timeline for human trial enrollment has been released.
The takeaway
The data highlights a potential mechanism for slowing cyst growth that outperforms metformin in laboratory models. Future updates will focus on HighTide Therapeutics' progress toward human trials and whether this suppression of renal inflammation translates to measurable clinical benefit.
Further reading
For more on the latest research in renal therapeutic development, visit the Biotech section.
Live Poll
Do you trust emerging medical research to provide meaningful improvements for chronic health conditions?
